Response within 8 days and durable response
In the pivotal, Phase 3, randomised study:
- 65.6% of patients on Doptelet achieved the ≥50 x 109/L platelet target by day 8*1
- Doptelet patients achieved a median of 12.4 weeks at or above target without rescue therapy*1
Effect and durable response regardless of prior treatment experience
- After switching to Doptelet, 93% of patients reached the ≥50 x 109/L platelet target†2
Doptelet is well tolerated and the most frequently reported adverse reactions (≥1/10) were headache and fatigue4
- Exposure-adjusted TEAEs 4.3% per patient week vs 6.6% with placebo*1
No food-type restrictions and no liver function monitoring4
- Doptelet should be taken with food – without any restrictions on meal composition, helping your patients stay compliant with therapy1,4–6
- Doptelet is the only oral TPO-RA that has not been associated with significant hepatotoxicity in clinical trials; no liver function monitoring is required1,4
*Vs 0.0% with placebo (P<0.0001), Phase 3 study. †Retrospective, observational TPO-RA switch study.
Doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).4
Doptelet is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure.4
ITP, immune thrombocytopenia; TEAE, treatment-emergent adverse event; TPO-RA, thrombopoietin receptor agonist.
References
1. Jurczak W et al. Br J Haematol. 2018; 183(3):479–490. 2. Al-Samkari et al. Br J Haematol. 2022; 197:359-366. 3. Al-Samkari H et al. Blood. 2021; 138(1):1015–1016. 03/2021. 4. Doptelet Summary of Product Characteristics. 22/05/2025. 5. Cheloff AZ and Al-Samkari H. J Blood Med. 2019; 10:313–321. 6. Tsykunova G and Ghanima W. Ther Clin Risk Manag. 2022; 18:273–286.